Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.39 |
| ▸ | IKBKB | O14920 | 4/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1823307 | 0.87 | KDM4E (0.34) | BRD4IKBKBJAK2JAK3ROCK1 | |
| SCHEMBL1827270 | 0.84 | BRD4 (0.42) | BRD4LIMK1IKBKBPRNPRXFP1 | |
| SCHEMBL1826459 | 0.76 | CDC7 (0.51) | BRD4IKBKBJAK2JAK3NPC1 | |
| SCHEMBL1826500 | 0.75 | CDC7 (0.50) | IKBKBJAK2JAK3CDC7 | |
| SCHEMBL2195802 | 0.74 | PTK2 (0.39) | BRD4IKBKBMEN1NPC1RAB9A | |
| SCHEMBL2198463 | 0.73 | BRD4 (0.52) | BRD4IKBKBJAK2JAK3ROCK1 | |
| SCHEMBL1828200 | 0.72 | RAB9A (0.44) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL2200146 | 0.72 | BRD4 (0.62) | BRD4IKBKBJAK2JAK3CDC7 | |
| SCHEMBL2199299 | 0.72 | IKBKB (0.42) | BRD4IKBKBJAK2JAK3MEN1 | |
| SCHEMBL1828542 | 0.71 | BRD4 (0.36) | BRD4JAK2ROCK1CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088817-B2 | Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | claimed |
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-06-09 | — | — | US | claimed |
| EP-2319831-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDE GROUP, AMINOCARBONYL GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | Santen Pharmaceutical Co., Ltd (JP) | 2011-05-11 | — | — | EP | claimed |
| US-8088817-B2 | Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088817-B2 | Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088817-B2 | Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| EP-2319831-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDE GROUP, AMINOCARBONYL GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | Santen Pharmaceutical Co., Ltd (JP) | 2011-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | IL6, IL6ST, UACA | BRD4 421/4885LIMK1 4543/4885IKBKB 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.